Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00362778

Acronym

INSUCOR

Enrollment

Registered

2006-08-10

Start date

2006-01-31

Completion date

2007-06-30

Last updated

2012-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Diabetes, Hyperglycemia

Brief summary

Hyperglycemia at admission has been associated with bad prognosis in patients with acute myocardial infarction (AMI). The clinical benefit of intensive treatment with insulin has been evaluated in diabetic patients admitted to intensive care units. The aim of our study was to assess the short-term effects and the safety of strict glycemic control in subjects with AMI and hyperglycemia without a previous history of diabetes.

Detailed description

Twenty-eight non-previously diabetic patients admitted with AMI and hyperglycemia were randomized to two treatment arms, administered during the first 48 hours: the intensive group (n=13) received intravenous insulin with target glycemia levels of 80-110mg/dL, while the conventional group (n=15) received subcutaneous insulin only when glycemia was ³ 160mg/dL. High-sensitivity C-reactive protein (HS-CRP) was determined at 48 hours and before discharge and an oral glucose tolerance test (OGTT) was performed at 1 month.

Interventions

DRUGInsulin

intravenous continuous insulin infusion for 48 hours

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Confirmed diagnosis of AMI, either with or without ST segment elevation 2. Presence of high blood glucose at admission with no previously known diabetes mellitus (DM)

Exclusion criteria

1. Age under 18 years old 2. History of DM 3. Presence of other cardiopathies (dilated cardiomyopathy, valvular or hypertrophic heart disease) 4. Unstable AMI patients (haemodynamic instability or arrhythmic disorders) 5. Platelet aggregation or coagulation disorders 6. Severe conditions with an estimated short (under 1 year) life expectancy 7. Participation in other trials 8. Patient refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Glycemic control	first 48 hours

Secondary

Measure	Time frame
High-sensitivity C-reactive protein levels	At 48 hours and aat hospital discharge

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026